Meta Pixel

News and Announcements

FDC Investment Strategy returned 3.2% net of fees 

  • Published October 31, 2019 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Capital Insights

The FDC Portaf fund is an  institutional grade fund that invests in funds that invest across the blockchain economy.

It mitigates risk and gains spread by investing in systematic trading of currencies and long only blockchain investments.

Outcome: Reduced risk and volatility with focus on consistent capital growth well above traditional market investments.

The Investment Strategy returned 3.2% net of fees for August.  The performance of each of the underlying funds into which the Investment Strategy has allocated was as follows:

  • The systematic arbitrage fund returned 9.1%,
  • The momentum trading fund returned 8.2%,
  • The high-frequency trading systematic arbitrage fund returned 3.7%,
  • The fundamental long/short (long biased) fund lost -7.1%.

The Investment Strategy was rebalanced at the end of August to reduce exposure to the HFT fund and the momentum trading fund and increase our holdings in cash to 12% in order to reduce risk during this period of increased volatility.

View full fact sheet here

 

About First Digital Capital

First Digital Capital’s – Portal Fund is a hedge fund that invests in a diverse spread of blockchain funds globally. We are very different to direct fund investing. With unprecedented access to premier global funds in blockchain and a robust risk management processes, First Digital Capital provide the Best of fund Access, deep Research and investment Diversity.

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now